Introduction
The human body contains more than 60,000 miles of blood vessels and an estimated 150,000 miles of lymphatic vessels, which together provide a conduit system for fluids, gases, chemical wastes and nutrients to and from body tissues. An additional function of the vasculature is transport of immune cells (leukocytes) to sites of inflammation. In order to escape the vasculature, leukocytes undergo a complex process whereby they tether, roll, adhere, spread and finally transmigrate through the endothelial cell layer lining blood vessel walls (Kelly et al. 2007; Yano et al. 2007 ). Each step in this cascade requires interactions of adhesion molecules on both cell types and research over the past few decades has uncovered the identity of key players in this process (Figure 1 ).
Extensive literature examining the role of protein glycosylation in leukocyte trafficking is available, but these studies have mainly focused on understanding how leukocyte glycans are involved in the process, while largely overlooking their heavily glycosylated endothelial cell binding partners (Huo and Xia 2009; Sperandio et al. 2009; Cooper et al. 2012) . Notable exceptions are studies that demonstrate a role for endothelial heparan sulfate (Wang et al. 2005) or L-selectin (via O-and N-glycosylation) , the latter in modulating lymphocyte trafficking to lymph nodes (Alon and Rosen 2007; Mitoma et al. 2007; Arata-Kawai et al. 2011 ). All of the endothelial cell adhesion molecules involved in leukocyte trafficking are heavily N-glycosylated. However, few studies have explored the potential for N-glycosylation to control adhesive functions of endothelial adhesion molecules with these studies generally indicating that an important role in fact does exist. An important consideration is that endothelial adhesion molecules which regulate leukocyte trafficking are often not expressed in quiescent cells. Moreover, N-glycan processing is distinctly controlled during inflammation and cellular dysfunction (Higai et al. 2003 (Higai et al. , 2005 Yasukawa et al. 2005; Arnold et al. 2008) . The combination then of inflammationdependent control of adhesion molecule expression and N-glycosylation could be a key aspect of innate immune responses and furthermore, dysregulation in this paradigm may be critical to the transition from an innate immune response to inflammatory disease.
The focus of this review will be to (i) highlight the heterogeneity between how leukocytes interact with endothelial cells in different vascular beds during inflammation (note that we limit our discussion to inflammation and will not focus on lymphocyte-HEV interactions). We posit that this is a consequence of both distinct functions between leukocyte subsets (monocytes versus neutrophils for example) and due to differential regulation of endothelial adhesion molecules N-glycosylation, (ii) to discuss what is known about changes in endothelial cell N-glycan processing during inflammation and (iii) to examine how the N-glycosylation status of a given adhesion molecule may regulate protein function during inflammation with comments on intracellular adhesion molecule-1 (ICAM-1, CD54), vascular cell adhesion molecule-1 (VCAM-1, CD106), platelet endothelial cell adhesion molecule-1 (PECAM-1, CD31) and the endothelial selectins (P-and E-selectin, CD62p and CD62e) as specific examples. Our goal is to coalesce these concepts to provide rationale for the working hypothesis that endothelial adhesion molecule N-glycans contribute to a "zip code" for targeted delivery of immune cells as well as disease-associated alterations in protein function.
Endothelial and leukocyte heterogeneity: Unique cell types with unique functions Endothelial cell development The cardiovascular system is the first vertebrate organ to function during embryogenesis when pluripotent endothelial progenitor cells from the mesoderm give rise to an early vascular plexus, thus forming the primitive heart (Heinke et al. 2012) . High-pressure contractions from this organ are transduced as mechanical forces that drive vasculogenesis and subsequent angiogenesis. During angiogenesis, early endothelial cells have two fates: become arterial or venous endothelial cells, with the latter having the potential to further differentiate into lymphatic endothelial cells. These subsequent endothelial cells have multiple functions and represent a barrier and sensor between the circulation and underlying tissues. From the perspective of inflammation, the endothelium is a critical effector in regulating how leukocytes egress into the subendothelial compartments.
Arterial and venous endothelial cell identity during the earliest stages of development is determined by the expression of Ephrin B2 (EphB2) in arteries and Ephrin B4 (EphB4) in veins (Wang et al. 1998; Gerety et al. 1999; Gerety and Anderson 2002) , which is controlled by vascular endothelial growth factor, Notch1 and other signaling regulators (Lawson et al. 2001 (Lawson et al. , 2002 Zhong et al. 2001; Fischer et al. 2004; You et al. 2005) . Venous endothelial cells can also further differentiate into lymphatic endothelial cells via Sox18-and Prox1-dependent signaling (Wigle and Oliver 1999; Wigle et al. 2002; Francois et al. 2008; Lee et al. 2009 ). The resulting vasculature is diverse in function with endothelial cells broadly different in size, growth rate and basal protein expression (Page et al. 1992; Thorin and Shreeve 1998) . Besides these major vessel subtypes, the body also contains numerous specialized vascular beds such as the highly fenestrated sinusoids in the liver or the virtually impermeable microvessels of the blood (Aird 2007a (Aird , b, 2012 . Current data clearly support the perspective that endothelial cells from different tissues and vascular beds cannot be grouped into one cell type, with their composition, function and how they respond during inflammatory stress being distinct.
Endothelial bed-specific responses to inflammatory stimuli Leukocyte emigration across the endothelium occurs in different vascular beds (e.g., ateries versus capillary versus venules), depending on the inflammatory stimulus, the organ system and disease under consideration (Aird 2007a, b) . This understanding has been critical to the general concept that the endothelial bed of origin is key in how these cells respond to Fig. 1 . Leukocyte adhesion cascade. Circulating leukocytes undergo a multistep process of rolling, slow rolling, arrest, adhesion and spreading and finally transendothelial migration to reach sites of underlying inflammation. Each step in this process is regulated by various adhesion molecules (indicated on Figure) expressed on the surface of endothelial cells. All of these proteins are N-glycosylated with emerging data suggesting that the process of N-glycosylation is regulated during inflammation independent of changes in adhesion molecule protein expression.
Endothelial N-glycans and inflammation inflammatory stimuli. Endothelial cells are subjected to a milieu of pro-inflammatory stimuli that promotes adhesion molecule expression. One such signal unique to the endothelium is the tangental shear forces imparted by flowing blood over the surface of the endothelial surface. In general, laminar blood flow, characterized by a pulsatile unidirectional flow of relative high force (>5 dynes/cm 2 ), is viewed as antiinflammatory while disturbed blood flow, characterized by directional flow changes and low net force (<5 dynes/cm 2 ), is seen as pro-inflammatory (Hahn and Schwartz 2009) . In vivo, disturbed flow is correlated with expression of adhesion molecules such as ICAM-1 and VCAM-1, which promotes leukocyte trafficking in diseases such as atherosclerosis (Hahn and Schwartz 2008) . Endothelial cells can also be activated by a variety of acute stimuli, including lipopolysaccharide, tumor necrosis factor alpha (TNFα), oxidized lipids and Interleukin-1β to name a few (Dauphinee, and Karsan 2006; Apostolakis et al. 2008; Sprague and Khalil 2009; Yoshimoto et al. 2011) . While all of these stimuli are characterized by endothelial cell activation leading to adhesion molecule expression, the temporal nature and severity of these responses are drastically different among endothelial cells from different vascular beds.
For example, TNFα stimulation of human umbilical vein endothelial cells (HUVECs) leads to an increase in ICAM-1, VCAM-1 and E-selectin expression, while the same treatment in human umbilical artery endothelial cells upregulates only ICAM-1 with increased monocyte binding occurring in the venous compared with the arterial cells. Yet, this study showed similar levels of NFκB activation in both cell types demonstrating preservation of inflammatory signaling, but divergence of cellular response (Kalogeris et al. 1999) . A similar study demonstrated that TNFα stimulation of either human iliac vein or iliac artery endothelial cells led to an increase in ICAM-1 and endothelial leukocyte adhesion molecule (ELAM)-1 (E-selectin) in both cell types, but upregulated VCAM-1 only in the cells from venous origin and increases in monocyte binding in both cell types but again with greater binding in the endothelial cells of venous origin (Hauser et al. 1993) . Oxidized low-density lipoprotein has been shown to activate arterial endothelial cells and upregulate ICAM-1, VCAM-1 and ELAM-1 (E-selectin) expression with no activation seen with cells of venous origin (Amberger et al. 1997) . Further studies examined endothelial cells from either mouse heart or lung (representing two distinct microvascular beds) and showed that cardiac endothelial cells expressed higher basal levels of VCAM-1, which was further increased with TNFα stimulation. Additionally, the ability of TNFα to upregulate ICAM-1, E-selectin and P-selectin was similar between the two cells types, but only cardiac endothelial cells demonstrated increased levels of the cytokines RANTES and macrophage inflammatory protein (MIP)2 chemokines again demonstrating vascular bed-specific effects on activation (Lim et al. 2003) . While the aforementioned effects were all seen in vitro, similar differences in response are also seen in vivo. TNFα stimulation of murine venules or arterioles leads to increased ICAM-1 expression in both vascular beds (Sumagin and Sarelius 2006) . However, basal levels of ICAM-1 are higher in the venuoles and stimulated arterioles only reach the basal expression levels of venuoles. This higher level of ICAM-1 in the venuoles is associated with increased leukocyte binding in both unstimulated and TNFα-stimulated conditions compared with the arteriole from the same animal.
Endothelial cells also respond differently to noncytokine receptor associated stimulation. A comparison of the response between human umbilical vein and dermal microvascular endothelial cells to protein kinase C agonist demonstrated increased VCAM-1 and E-selectin expression only in the HUVECs (Mason et al. 1997) . Endothelial cells from different vascular beds also show heterogeneity in response to shear stress. A comparison of arterial or venous cells exposed to pro-inflammatory flow (2.2 dynes/cm 2 ) demonstrated elevated shear-induced ICAM-1 upregulation in venous cells compared with arterial cells (Methe et al. 2007 ). This study also demonstrated that costimulation with TNFα and flow resulted in increased E-selectin and VCAM-1 in venous cells, but not arterial endothelial cells. Collectively, the studies discussed above represent a small fraction of the literature that demonstrates that endothelial origin dictates response to stimuli and underscores the importance of choosing a proper combination of stimulus and endothelial cell bed origin to best mimic the pathology being investigated.
Lectin-binding patterns vary between vascular beds
Several studies have characterized endothelial N-glycans from a diverse set of vascular beds across several species (Table I ). An examination of lectin binding in the vasculature of Atlantic hagfish demonstrated binding of lectins LCA, UEA, RCA, isolectin B4 and DBA in endothelial cells of the large artery and vein, but not in the heart or liver, demonstrating macro-versus microvascular differences in glycan patterns (Yano et al. 2007) . Lectin binding studies in rat microvasculature demonstrated that ConA, LCA, LEA, RCA and WGA were able to bind to all beds tested, while HPA and GS1 only reacted with certain vascular beds (Smolkova et al. 2001) . Studies measuring lectin binding to the vasculature of developing chicken embryos found that ConA, LCA and WGA could be used to identify all endothelial cells at early developmental stages (E2.5-E4). However, as development progressed, only LCA was able to bind to endothelial cells of all vessels (Jilani et al. 2003) . Another study examined the reactivity of a panel of lectins toward the vasculature of 15 species including samples of human, equine, bovine, porcine and murine origin. The results demonstrated a pattern of lectin binding that was not universal and displayed an evolutionarily conserved hierarchy (Roussel and Dalion 1988) . When taken together, these studies demonstrate that carbohydrates (including N-glycans) decorating the surface of endothelial cells are unique signatures of the vascular bed and species of origin and again reinforce the concept of significant heterogeneity among endothelial cells from different vascular beds.
Endothelial N-glycans are modified during inflammation A number of recent studies have examined the effects of pro-inflammatory stimuli on glycan processing enzymes DW Scott and RP Patel and surface glycan expression of isolated human endothelial cells (Table I) . One study examined the expression of 74 glycosylation-related genes comparing HUVECs with human foreskin microvascular endothelial cells (FMVEC), as well as HUVECs in an untreated or TNFα-stimulated state (Garcia-Vallejo et al. 2006 ). The authors found that 19 of the 74 genes displayed significant differences between the cell types under basal conditions including such differences as elevated ST6GAL1 in HUVECs and elevated C2GnT-2 in FMVEC. These differences in gene expression were confirmed by increased SNA staining in HUVEC compared with FMVEC and increased PWM staining in FMVEC compared with HUVEC. With TNFα stimulation of HUVECs, there was an increase in genes encoding for fucosylation (FUT1, FUT4), which corresponded to an increase in UEA1 binding, as well as an increase in ST6GAL1 expression and associated SNA binding, compared with unstimulated cells. Surprisingly, the authors also saw an increase in ConA staining in the TNFα-stimulated HUVECs suggesting an increase in hypoglycosylated N-glycans on the cell surface. An increase in ConA staining has also been described in HUVECs exposed to pro-inflammatory tumor conditioned medium (Peng et al. 2010) . In this study, there was also an increase in SNA and DSA binding, suggesting the presence of α2,6-sialylation and branched N-glycans in conjunction with the increase in hypoglycosylated structures. Our own findings, which to our knowledge are the only studies that have examined the effects of inflammation on N-glycan changes in human arterial endothelial cells, have shown that ConA binding is increased in human aortic endothelial cells (HAECs) exposed to TNFα (Chacko et al. 2011) and disturbed blood flow (Scott et al. 2012) . As in previous studies, we observed an increase in ST6GAL1 transcript with TNFα treatment, but we also observed decreased expression of genes involved in early N-glycan trimming and branching (MAN1A1, MAN1A2, MAN1C1 and MGAT1) as well as a decrease in α-mannosidase activity. Interestingly, disturbed flow, which is pro-inflammatory, decreases MAN1A1 expression in HUVECs compared with cells exposed to laminar flow, further implicating early N-glycan processing enzymes as targets during inflammation (Mun et al. 2009 ). Interestingly, α-mannosidase activity is significantly decreased in the aortas of streptozotocin-induced diabetic rats compared with healthy littermates (Wolinsky et al. 1978) . Diabetes is known to induce systemic inflammation, which can be controlled in part by normalizing hyperglycemia by insulin administration. In this study, administration of insulin to streptozotocin-treated rats restored normal α-mannosidase enzyme activity in the rat aorta demonstrating that hyperglycemia-associated factors, most likely inflammation, was responsible for the decrease in enzyme activity.
Collectively, these studies demonstrate that endothelial cell dysfunction that occurs during inflammation leads to pronounced changes in N-glycan processing mechanisms and surface N-glycan content with one general consensus being that pro-inflammatory stimuli increase hypoglycosylated (high-mannose/hybrid) N-glycans on the cell surface as determined by ConA staining. Other studies have also described similar increases in ConA reactivity in endothelial cells. One such study found that subconfluent and migrating endothelial cells had higher surface ConA reactivity compared with resting confluent cells (Augustin-Voss and Pauli 1992) and wound-healing assays have shown an increase in ConA staining at the migrating leading-edge of the cell compared with the intact monolayer (Ball et al. 1989) , which has also been described in other cell types (Kucik et al. 1989) .
Importantly, this conclusion is also supported from studies comparing patterns of lectin binding in human tissues under healthy and diseased states. Examination of lectin binding to umbilical cords demonstrated increased ConA and UEA binding to the vein compared with the artery and lectinbinding patterns during pregnancy complications are altered in both pattern and intensity within the vasculature (Sgambati et al. 2003 (Sgambati et al. , 2007 . Our own studies have shown that there Scott et al. (2012) .
Endothelial N-glycans and inflammation is low reactivity of ConA and LCA toward coronary and carotid artery endothelial cells of healthy patients but increased relative reactivity in the same vascular beds during early atherosclerotic development, which corresponds to increased adhesion molecule expression and leukocyte trafficking in these samples (Funk et al. 2012; Scott et al. 2012) .
Leukocyte subsets and function
Leukocytes encompass five distinct subfamilies of immune cells including neutrophils, monocytes, eosinophils, basophils and T-lymphocytes. All of the cells have a common progenitor, which subsequently differentiates into a myeloid lineage cell that gives rise to monocytes, neutrophils, eosinophils and basophils (as well as erythrocytes) and a lymphoid progenitor that gives rise to T-cells (Kawamoto and Katsura 2009; Kondo 2010 ). Apart from these major subtypes, there are additional subfamilies. For example, T-cells can be subdivided further in to Th1, Th2, Th17 and Treg cells (McGeachy and Cua 2008; Sakaguchi 2011; Jin et al. 2012) , each of which is characterized by its own inflammatory phenotype and monocytes can be subdivided by expression of Ly6c in mice, and CD14/CD16 in humans ). Additionally, monocytes can give rise to macrophages and dendritic cells, both of which have additional cellular subtypes such as the pro-inflammatory M1 or antiinflammatory M2 macrophage (Auffray et al. 2009; Geissmann et al. 2010) . When attempting to differentiate these cells from one another, researchers often rely on analysis of surface receptors, many of which happen to be adhesion molecules, on a particular cell type. In this manner, distinct subsets and subtypes of leukocytes have the ability to differentially bind endothelial adhesion molecules, and among these leukocyte receptors are a number of proteins that recognize saccharides (Ross 2002; van Kooyk and Geijtenbeek 2002; Xia et al. 2002; Taylor and Drickamer 2007; O'Brien et al. 2012) .
There is also heterogeneity in regard to which leukocytes are recruited to sites of inflammation. For example, during atherosclerosis development, there is specific recruitment of monocytes during the early stage of the disease which differentiate into pro-inflammatory foam cells that participate in the recruitment of other immune cell types such as neutrophils and T-cells as the disease develops (Libby 2002; Ross 2002; Xia et al. 2002; Soehnlein 2012) . Further, it has been shown that N-glycan branching and formation of complex N-glycans shifts the asthmatic response from being eosinophilic to neutrophilic in mice (Bahaie et al. 2011; Shibui et al. 2011 ) and promotes autoimmune-associated T-cell activation (Chen et al. 2009; Grigorian and Demetriou 2011; Mkhikian et al. 2011) . Moreover, accumulation of endothelial high-mannose N-glycans inhibited lymphocyte static adhesion (Renkonen and Ustinov 1991) , whereas these glycoforms are involved in increased monocyte rolling and adhesion (assessed during flow conditions) (Chacko et al. 2011; Scott et al. 2012 ). This discussion together with endothelial heterogeneity considerations underscores the complexity of inflammatory regulatory mechanisms. We also suggest that simply stating that leukocytes are being studied is not informative with respect to understanding mechanisms without defining which specific cell type and the disease-appropriate context (discussed further below).
Glycosylation controls endothelial adhesion molecule function
Below, we discuss studies that demonstrate how differential N-glycosylation of select endothelial adhesion molecules affects both leukocyte capturing and endothelial signaling functions of these proteins. In this context, it is important to remember that the protein acts as a physical scaffold for the N-glycan and that proper function of the adhesion molecule depends on both entities (illustrated in Figure 2 ).
Intercellular cell adhesion molecule-1
Of all the endothelial adhesion molecules, the role of N-glycosylation on ICAM-1 function is by far the best studied. Human ICAM-1 contains eight confirmed N-glycosylation sites (Bloom et al. 1996) . Addition of N-glycans is required for transport of ICAM-1 to the endothelial cell surface as Fig. 2 . Working hypothesis model of endothelial "zip code" mediated leukocyte adhesion. Circulating leukocytes encounter a variety of vascular beds throughout the body with unique combinations of proteins and sugars expressed on their surfaces. Only under the correct conditions, when the appropriate adhesion molecule protein and corresponding N-glycan are expressed will efficient leukocyte adhesion be achieved. In this model, the adhesion molecule provides a protein scaffold which is necessary, with the associated N-glycans being conditional, but required to support leukocyte adhesion under flow.
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pretreatment with tunicamycin prevents trafficking of the protein (Scott et al. 2012 ) and cells unable to construct N-glycans display reduced surface ICAM-1 expression (He et al. 2012 ). However, inhibition of mannose trimming with kifunensine or swainsonine does not alter surface trafficking nor expression levels, so the mere addition of N-glycans appears to be sufficient for plasma membrane delivery (Scott et al. 2012 ). To date, no studies have examined whether any of the eight N-glycan sites are required for transport.
ICAM-1 serves multiple functions; it is a ligand for the cognate leukocyte integrins leukcoyte function-associated antigen (LFA)-1 (CD11a/CD18) (Makgoba et al. 1988 ) and Mac1 (CD11b/CD18) (Diamond et al. 1990 ), binds human rhinovirus (Greve et al. 1989; Staunton et al. 1989) , regulates endothelial junctional integrity (Allingham et al. 2007 ) and regulates cellular glutathione production (Kevil et al. 2004 ). While ICAM-1 is best known to play a role in leukocyte adhesion, multiple studies clearly demonstrate that it can also support rolling (Forlow and Ley 2001; Dunne et al. 2003 ). An essential role in immunity is evident from studies with mice deficient in ICAM-1 which display impaired inflammatory responses (Sligh et al. 1993) . ICAM-1 can also be produced in a soluble ICAM-1 (sICAM-1) form whereby it activates immune cells to induce pro-inflammatory response (Otto et al. 2004) .
The first direct evidence of ICAM-1 glycosylation regulating function was demonstrated when protein produced in the presence of the Class 1 α-mannosidase inhibitor 1-deoxymannojirimicin (DMJ) showed increased binding with Mac1. In this same study, deletion of two asparagines residues which carry N-glycans (N240 and N269) lead to a dramatic increase in Mac1 binding (Diamond et al. 1991) . A later study demonstrated that HUVECs activated with TNFα in the presence of DMJ had increased neutrophil adhesion under static (no-flow) conditions compared with TNFα stimulation alone. This increase in adhesion could be blocked by antibodies against ICAM-1 or CD18, suggesting that highmannose ICAM-1 can function in leukocyte firm-adhesion (Sriramarao et al. 1993) .
While not a direct role in function per se, N-glycosylation is also a regulator of rhinovirus binding. Human rhinovirus binds to the IgG-like domain 1 of ICAM-1, but not to ICAM-1 of nonprimates. This phenomenon results from an N-T mutation at amino acid 20 that interestingly also destroys an N-glycosylation sequon. Point mutation to restore this N-glycan site in human ICAM-1 blocks rhinovirus binding (Bella et al. 1998; Jimenez et al. 2005) . Alternatively, we have hypothesized that high-mannose N-glycan structures on human ICAM-1 are important in mediating monocyte rolling and adhesion to aortic and umbilical vein endothelial cells (Chacko et al. 2011; Scott et al. 2012) . It is interesting to speculate that some N-glycan-binding sites on ICAM-1 may be pro-adhesive, whereas neighboring sites may be antiadhesive, underscoring the potential breadth of how ICAM-1 function may be regulated by N-glycosylation.
Glycosylation can also regulate sICAM-1 function. sICAM-1 produced from Chinese hamster ovary (CHO) cells stimulates MIP-2 production from murine astrocytes (Otto et al. 2004) . sICAM containing only high-mannose N-glycans is 26-fold less potent in inducing MIP-2 expression. However, each of these sICAM-1 glycoforms retains normal binding to LFA-1, demonstrating that different glycoforms of sICAM-1 can support unique functions. Additionally, this paper demonstrated the critical point that in contrast to CHO cells, sICAM-1 produced in HEK cells is unable to activate MIP-2 secretion from murine astrocytes. This suggests that CHO and HEK cells impart a unique "glycan fingerprint" on sICAM-1 that modulates function. This concept is supported by a previous report where human sICAM-1 was produced in CHO, HEK and murine myeloma cells and the respective N-glycomes were assessed by mass-spectrometry analysis (Bloom et al. 1996) . This study found that each cell type produced ICAM-1 with a distinct N-glycan pattern. When endothelial cell heterogeneity is taken into consideration, it is easy to hypothesize that distinct ICAM-1 glycoforms could be present in different regions of the vasculature leading to diverse functions and efficiencies as described above.
Vascular cell adhesion molecule-1
In humans, VCAM-1 contains six potential N-glycan sites, but to date only one of those sites has been confirmed by mass-spectrometry analysis (Liu et al. 2005) . VCAM-1 can mediate leukocyte rolling and adhesion through interactions with very late antigen (VLA)-4 (Berlin et al. 1995; Reinhardt et al. 1997; Mazo et al. 1998 ) and recent evidence suggests that galectin proteins may also be involved (Rao et al. 2007; Tadokoro et al. 2009 ). As with ICAM-1, tunicamycin completely prevents surface expression of VCAM-1, but inhibition of mannose trimming does not inhibit trafficking (Scott et al. 2012) . HUVECs stimulated with tumor conditioned media express VCAM-1 that segregates into at least five distinct populations by 2-D gel electrophoresis (Montes-Sanchez et al. 2009) . Observations that galectin-3 binds VCAM-1 (Rao et al. 2007; Tadokoro et al. 2009 ) suggests that at least some of the VCAM-1 N-glycans do not contain terminal sialic acid. In support of this, previous work has shown that removal of α2,6-but not α2,3-sialic acid from VCAM-1 increases lymphocyte binding under flow (Abe et al. 1999) . In contrast, lectin microarray studies indicate that galectin-3 does recognize α-2,3 and α-2,6 sialic acids (Stowell et al. 2008 ). This study demonstrated that galectin-3-mediated binding to human promyelocytic leukemia cell line (HL-60) cells was not further reduced by the α-2,3/α-2,6 sialidase from Clostridium perfringens when compared with the effects of the α-2,3 specific sialidase from Salmonella typhimurium. These data suggest that physiological recognition of sialic acid by galectin-3 is α-2,3 specific. However, previous studies have shown that endothelial cells do not increase α-2,3-linked sialic acid during inflammation (Hanasaki et al. 1994) , and there have been no reports of α-2,3 decorated VCAM-1, suggesting that Galectin-3 binding to VCAM-1 most likely occurs via interactions with galactose (Rao et al. 2007 ).
E-selectin/P-selectin
The endothelial selectins, E-and P-selectin are known to mediate leukocyte tethering and rolling via interactions with leukocyte expressed P-selectin glycoprotein ligand (PSGL)-1 and E-selectin ligand-1 (McEver 2004; Zarbock et al. 2011;  Endothelial N-glycans and inflammation Chase et al. 2012 ). These two molecules are grouped together due to some redundancy regarding their function as mice null for either one of the proteins maintain a normal immune response while mice lacking both genes have reduced leukocyte trafficking and immune responses (Bullard et al. 1996; Frenette et al. 1996; Jung and Ley 1999 ). E-selectin contains 11, while P-selectin contains 9 potential N-glycans but to date no study has confirmed this by mass-spectrometry. Much like ICAM-1, the addition of N-glycans is required for surface transport of E-selectin but maturation to complex N-glycans is not an absolute requirement (Pahlsson et al. 1995 ). E-selectin in IL1β-induced HUVEC is resistant to EndoH digestion, suggesting that the N-glycans are of the hybrid/complex variety. Further, this study showed that deglycosylated E-selectin ( peptide N-glycosidase F digested) retained full ability to bind HT-29 cells, suggesting that the N-glycans of E-selectin are not involved in function, only in transport. We are unaware of other studies examining E-selectin N-glycosylation or any studies that have examined the role of P-selectin N-glycosylation in protein transport or function.
Platelet endothelial cell adhesion molecule-1 PECAM-1 is highly and ubiquitously expressed on all endothelial cells, but is also expressed on platelets and most leukocyte subsets. On endothelial cells, PECAM-1 performs a variety of functions including transduction of mechanical signals (Tzima et al. 2005) , maintenance of endothelial barrier integrity (Privratsky et al. 2010 ) and protection against apoptosis, and is directly involved in leukocyte diapedesis (Muller et al. 1993 ). The human PECAM-1 protein contains nine potential N-glycan sites and the protein is known to be heavily N-glycosylated (Newton et al. 1999) . A recent study demonstrated that α2,6-sialic acid is required for surface retention of PECAM-1 (Kitazume et al. 2010 ) as surface PECAM-1 levels on endothelial cells isolated from ST6GAL1 −/− mice were significantly lower than wild type. However, this study stands in contrast to previous reports that suggested α2,6-sialic acid was not present on PECAM-1 or required for its surface organization (Geyer et al. 1999) . In this earlier study, it was observed by confocal microscopy that the α2,6-sialic acid specific lectin SNA colocalizes at apical surface endothelial cell junctions with the junctional protein VE-Cadherin but did not colocalize with PECAM-1. These authors further demonstrated that sialidase treatment of endothelial monolayers resulted in disruption of VE-cadherin but not PECAM-1 organization. The above discussion highlights the potential but also underscores how little is known on how N-glycans modulate PECAM-1 function: a conclusion that can be applied to all the endothelial adhesion molecules.
While the above discussion highlights some of the most extensively investigated endothelial adhesion molecules, many others do exist including CD44, members of the junctional adhesion molecule (JAM) family, ICAM-2, ICAM-3, mucosal addressin cell adhesion molecule-1 and others. While some studies have examined the role of N-glycans in the functions of these proteins (de Fougerolles et al. 1995; Skelton et al. 1998; Weber et al. 2004) , few studies have focused on endothelial cell expression or disease appropriate conditions.
Other considerations
Host species makes all the difference As mice serve as the major in vivo models for inflammation research, conservation of N-glycosylation across species must be addressed. Profound differences in potential N-glycosylation sites in proteins from humans and mice exist. For example, human ICAM-1 contains eight, while murine ICAM-1 contains 10 N-X-S/T motifs, but only four of the motifs are conserved between the species. Of note, the two glycosylation sites in ICAM-1 that are known to regulate Mac1 binding (Diamond et al. 1991) are absent in murine ICAM-1 and loss of a N-glycosylation site in the IgG-like 1 domain of human ICAM-1 allows for rhinovirus binding, while the presence of this site in murine ICAM-1 prevents binding. Thus, examining the role of N-glycosylation in murine ICAM-1 and extrapolating the results to the human protein would seem imprudent. Similar differences are seen with other adhesion molecules also. Finally, while mice serve as the major model system for in vivo analysis, endothelial cells from bovine and porcine aorta represent prominent in vitro models. As with the comparison of N-glycan sites between mouse and humans, further analysis incorporating porcine and bovine N-glycan patterns demonstrates that few sites are conserved amongst all four species (Table II) . Moreover, the leukocyte receptors which bind endothelial cell adhesion molecules are also highly N-glycosylated and a similar pattern of species specific sites and overall lack of conservation is seen (Table III) .
Despite the understanding for many years now that inflammation and leukocyte-endothelial rolling and adhesion are key elements in numerous acute and chronic inflammatory diseases, few antiadhesion targeted therapies have been developed successfully into the clinical arena. This lack of success is even more puzzling since the major protein (adhesion molecule) players are known and various strategies (knockout, antibody blocking etc) have shown very good efficacies in preclinical experimental studies. We speculate that differences in N-glycan content, composition and regulation in mice versus humans is a possible reason for the poor translation of antiendothelial adhesion molecule therapies into the clinic and posit that success may occur only after integration of the understanding of how N-glycans modulate endothelial adhesion molecule function with respect to both leukocyte rolling/ adhesion and signaling into current paradigms. 8  10  13  12  3  3  VCAM-1  6  7  3  5  3  3  E-selectin  9  11  10  7  2  3  P-selectin  11  12  11  11  6  2  PECAM-1  9  7  10  8  4  1  JAM 3  3  2  2  3  2  0  ICAM-2  6  5  6  6  3  1 Human specific denotes the number of unique N-glycosylation sequence motifs.
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The curious case of sialic acid: Insights from E-selectin A proper discussion of the role of glycans in leukocyte trafficking that does not mention sialyl Lewis X (sLe x ) structures would be inappropriate. While these structures are most often associated with O-glycans, it is their prominent role as ligands to the endothelial cell selectins that make them relevant in the current discussion. Many biochemical, in vitro and in vivo studies have confirmed that sLe x is a selectin ligand (Phillips et al. 1990; Walz et al. 1990 ) and based on this, a role for sialic acid in leukocyte trafficking has been extensively investigated with interference of selectin/sLe x interactions being a focus for therapeutic development for multiple diseases (Norman et al. 1998; De Vleeschauwer et al. 2001 ).
However, a natural variant of E-selectin exists as S128R which cannot recognize sLe x motifs (Rao et al. 2002) . S128R E-selectin has been shown to bind nonfucosylated K562 cells and is able to bind neuraminidase treated HL-60 cells, both of which cannot bind to wild-type E-selectin, clearly demonstrating that this naturally occurring E-selectin mutant can bind ligands other than sLe x (Revelle et al. 1996; Rao et al. 2002) . If selectin/sLe x were required for leukocyte trafficking, it would be expected that persons carrying this mutation would be protected from inflammation; in contrast however, the S128R mutation is associated with increased risk for coronary artery disease (Wenzel et al. 1996; Ghilardi et al. 2004) , cancer (Nadi et al. 2007; Khazen et al. 2009; Liarmakopoulos et al. 2012) , and importantly with increases in leukocyte trafficking (Khazen et al. 2009; Liarmakopoulos et al. 2012) . To date, several mouse models that have reduced ability to express sLe x structures or deletion of endothelial selectins have been produced. Specifically, mice lacking the ability to generate core 2 O-glycans, the major backbone of sLe x , due to loss of C2GlcNacT-1 (Sperandio et al. 2001) or mice lacking enzymes important for the addition of α2,3-sialic acid ST3Gal4 (Sperandio et al. 2006) or ST3Gal4 and ST3Gal6 ) display decreases in leukocyte rolling and trafficking. Interestingly, this inhibition appears to be selective for neutrophils over other leukocyte subsets. A similar phenomenon is seen in mice lacking expression of all the three selectin proteins (E-, P-and L-selectin). In this study, leukocyte trafficking across TNFα-stimulated murine cremaster venuoles demonstrated a decrease in total leukocyte rolling, but only a decrease in neutrophils trafficking to the surrounding tissue (Jung and Ley 1999) . In fact, this study actually showed an increase in the number of monocytes and eosinophils in the TNFα-stimulated venuoles from selectin triple knockout mice compared with wild-type mice. So, these studies indicate that while sLe x is involved in the trafficking of some leukocytes it is not required for others. It is interesting to speculate therefore that some of the apparently disparate experimental observations, as highlighted above with E-selectin and sLe x interactions, maybe due to the type of leukocyte employed in assessing inflammation. We appreciate that this discussion is limited since it stems primarily from E-selectin related data. That said, the data do suggest a model in which a monocyte may interact with the same endothelial adhesion molecule as a neutrophil, but not only may the position on the protein (dictated by primary sequence and tertiary/quaternary structures) where these cells bind be different, how the same glycan structure modulates monocyte or neutrophil adhesion may also be different.
As discussed above, several reports have indicated that pro-inflammatory treatment of endothelial cells increases α2,6-sialic acid expression as determined by increased SNA staining (Diamond et al. 1990; Garcia-Vallejo et al. 2006) . In these studies, investigators examined SNA binding after prolonged stimulation with pro-inflammatory treatment. Our own findings indicate that there is no increase in SNA binding in TNFα-stimulated HUVEC or HAEC at earlier (<4 h) times (Scott et al. 2012 and unpublished data) , which is supported by work showing that SNA binding to TNFα-stimulated endothelial cells only begin to increase after six hours of stimulation (Hanasaki et al. 1994) . Importantly, adhesion of monocytes is comparable at 4 and 24 h poststimulation with multiple stimuli further suggesting that endothelial cell expressed sialic acid is not critical for, in this case monocyte, adhesion (unpublished data). Additional work suggests that endothelial cell expressed sialic acid is not involved in leukocyte adhesion (Giuffre et al. 1997; Abe et al. 1999 ) and a negative role for complex N-glycans, and likely sialic acid, has been reported. Kidney epithelial cells grown in the presence of swainsonine, show increased junctional integrity (Vagin et al. 2008 ) and inhibition of N-glycan branching has been shown to increase cancer cell adhesion to extracellular matrix proteins (Przybylo et al. 2005) . Our own work has demonstrated that pretreatment of endothelial cells with kifunensine or swainsonine increases monocyte adhesion (Scott et al. 2012) again demonstrating that N-glycan complexity is inversely correlated with cell adhesion in certain contexts.
Final thoughts
Adhesion molecules are central players in the inflammatory component of innate immunity and a host of diseases. The role of N-glycans on endothelial adhesion molecule function remains unclear. The tacit assumption has been that like all N-glycosylated proteins, N-glycans are important in targeting adhesion molecules for cell-surface expression and/or secretion. However, it is becoming evident that adhesion molecule N-glycosylation is a dynamic process regulated during inflammation by mechanisms that operate in parallel, but are distinct to up-regulation of protein expression. Moreover, specific N-glycan structures may impart unique functions to adhesion Human specific denotes the number of unique N-glycosylation sequence motifs.
Endothelial N-glycans and inflammation molecules including providing ligands for cognate leukocyte receptors (i.e., a zip code) and modulating endothelial signaling. This paradigm is further complicated as no general function can be ascribed to any given N-glycan modification with multiple variables including the nature of the protein, the nature of N-glycan structure(s), the site on the protein of these glycans, inflammatory stimulus involved and vascular bed all determining the ultimate function. We posit that a more comprehensive understanding of a given adhesion molecules N-glycan complement and function, and the assessment of this function in vitro and in vivo, is critical to fully delineate the functions of proteins and how they are regulated and hypothesize that with this understanding, new therapeutic targets for treating inflammatory diseases will emerge.
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